Ideas to Action:

Independent research for global prosperity

X

CGD Podcast

Feed

Tom BollykyFueled by charitable giving, more and more medical research is focusing on treating and curing thus-far neglected diseases. Is the regulatory framework ready? My guest this week is Tom Bollyky, a visiting fellow here at the Center for Global Development. Tom is a lawyer by training, and is currently working on the important legal and regulatory issues surrounding clinical trials for medicines to treat neglected diseases.

For those unfamiliar with the scale of the problem, Tom gives a quick introduction to what neglected diseases are. Common diseases like malaria and tuberculosis and less common diseases like dengue fever and hookworm together afflict more than one billion people worldwide. Yet, because they’re not big problems in high income countries, very little research has gone towards finding cures for them.

The Gates Foundation has led the way by putting billions of dollars into new biomedical research, which is starting to pay off. But as Tom explains, new treatments coming down the pipeline must undergo rigorous clinical trials, often in countries that lack the capacity to properly carry out and monitor those trials. Weak regulatory capacity can endanger test subjects, says Tom, and also decreases the value of the trials that do take place. “A clinical trial is just a scientific experiment. But if it’s not appropriately regulated and monitored,” Tom says, “the validity of that experiment comes into question and the investment is useless.”

Beyond basic safety, the clinical trials infrastructure struggles to handle the sorts of complex, multi-drug treatments that show the most promise to treat certain diseases. And, Tom says, trying to navigate the current system can be a headache. One ongoing trial for a malaria vaccine had to clear 40 independent review boards—many reviewing the exact same procedures against different standards.

Tom is leading a working group that will issue recommendations for how the clinical trials process could be improved and streamlined. For a deeper look at the issues the working group will be addressing, you can read Tom’s working paper on the clinical trials process or watch video of his recent testimony before Congress.

Have something to add to our discussion? Ideas for future interviews? Post a comment below, or send me an email. If you use iTunes, you can subscribe to get new episodes delivered straight to your computer every week.

My thanks to Wren Elhai for his very able production assistance on the Wonkcast recording and for a draft version of this blog post.

Related Topics:

Disclaimer

CGD blog posts reflect the views of the authors, drawing on prior research and experience in their areas of expertise. CGD is a nonpartisan, independent organization and does not take institutional positions.